SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines

Submitted by Anonymous on

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines Published on 11/08/2025 at 10:12 am EST Publicnow Share Bicara Therapeutics Inc. +0.48%...

Discordance in Creatinine- and Cystatin C–Based eGFR and Clinical Outcomes: A Meta-Analysis

Submitted by Anonymous on

: A Meta-Analysis : A Meta-Analysis Key Points Question Do individuals with a cystatin C–based estimated glomerular filtration rate (eGFRcys) value at least 30% lower than their creatinine-based estimated glomerular filtration rate (eGFRcr) have higher rates of mortality, cardiovascular events,...

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Submitted by Anonymous on

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed...

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor ORIC Pharmaceuticals Thu, November 6,...

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

Submitted by Anonymous on

**media[814170]**BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinomaThis Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics commercialization capabilitiesSUZHOU, China, Nov. 5, 2025 /PRNewswire/...

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

Submitted by Anonymous on

BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics commercialization capabilities SUZHOU, China, Nov. 5, 2025...

Anti-tumor efficacy and Vδ2 T-cell activation via EGFR antibody-drug conjugates featuring novel aminobisphosphonates

Submitted by Anonymous on

Antibody–drug conjugates (ADCs) represent a promising strategy in cancer therapy, enabling the targeted delivery of cytotoxic agents to tumor cells. In this study, we developed and characterized novel ADCs combining the anti-EGFR monoclonal therapeutic antibody Cetuximab (Cet) with two aminobisphosphonates...

Subscribe to Newsfeed